D. E. Shaw & Co., Inc. Edgewise Therapeutics, Inc. Transaction History

D. E. Shaw & Co., Inc.

$100 Billion
Q1 2025

A detailed history of D. E. Shaw & Co., Inc. transactions in Edgewise Therapeutics, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 140,548 shares of EWTX stock, worth $2.08 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

140,548

Previous 686,371 79.52%

Holding current value

$2.08 Million

Previous $18.3 Million 83.13%

% of portfolio

0.0%

Previous 0.02%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$22.0 - $30.03 $12 Million - $16.4 Million	-545,823 Reduced 79.52%	140,548 $3.09 Million
Q4 2024 Feb 14, 2025	BUY	$26.63 - $36.62 $6.15 Million - $8.46 Million	231,023 Added 50.74%	686,371 $18.3 Million
Q3 2024 Nov 14, 2024	BUY	$15.88 - $29.5 $2.28 Million - $4.24 Million	143,872 Added 46.19%	455,348 $12.2 Million
Q2 2024 Aug 14, 2024	SELL	$15.08 - $21.23 $2.45 Million - $3.44 Million	-162,204 Reduced 34.24%	311,476 $5.61 Million
Q1 2024 May 15, 2024	BUY	$9.25 - $19.97 $4.09 Million - $8.82 Million	441,730 Added 1382.57%	473,680 $8.64 Million
Q4 2023 Feb 14, 2024	BUY	$5.51 - $12.1 $176,044 - $386,595	31,950 New	31,950 $349,000
Q1 2023 May 15, 2023	BUY	$6.66 - $11.33 $89,656 - $152,524	13,462 Added 119.41%	24,736 $164,000
Q4 2022 Feb 14, 2023	BUY	$7.58 - $11.08 $85,456 - $124,915	11,274 New	11,274 $100,000
Q4 2021 Feb 14, 2022	SELL	$14.41 - $22.41 $197,344 - $306,904	-13,695 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$14.11 - $24.1 $458,179 - $782,575	-32,472 Reduced 70.34%	13,695 $227,000
Q2 2021 Aug 16, 2021	BUY	$21.33 - $30.25 $984,742 - $1.4 Million	46,167 New	46,167 $985,000

Others Institutions Holding EWTX

# of Institutions

222

Shares Held

105M

Call Options Held

2.57M

Put Options Held

1.58M

View Full List

About Edgewise Therapeutics, Inc.

Ticker EWTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 63,171,700
Market Cap $936M
Description
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has c...

More about EWTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account